Gong H, Tashkin D P, Simmons M S, Calvarese B, Shapiro B J
Clin Pharmacol Ther. 1984 Jan;35(1):26-32. doi: 10.1038/clpt.1984.4.
The bronchodilating activity of oral cannabinoids was evaluated in three double-blind experiments that involved the study of dose-response and interactive relationships and the potential development of tolerance. Data indicated that delta 8-tetrahydrocannabinol (delta 8-THC), cannabinol (CBN), and cannabidiol (CBD) in maximal doses of 75 mg, 1200 mg, and 1200 mg, respectively, did not induce significant dose-related physiologic effects in experienced marijuana smokers. delta 8-THC (75 mg) was, however, associated with bronchodilation, tachycardia, and peak highs less than that after delta 9-tetrahydrocannabinol (delta 9-THC). The combinations of CBN and CBD with low-dose delta 9-THC (5 mg) did not induce significant bronchodilation but did exert interactive effects on heart rate and "high." A 20-day study of daily delta 9-THC (20 mg), CBN (600 mg), and CBD (1200 mg) did not indicate tolerance or reverse tolerance to any drug. We conclude that delta 9-THC and, to a lesser extent, delta 8-THC, have acute bronchodilator activity but that CBN, CBD, and their combinations do not provide effective bronchodilation. The daily use of delta 9-THC was not associated with clinical tolerance.
在三项双盲实验中评估了口服大麻素的支气管扩张活性，这些实验涉及剂量反应和相互作用关系的研究以及耐受性的潜在发展。数据表明，最大剂量分别为75毫克、1200毫克和1200毫克的δ8-四氢大麻酚（δ8-THC）、大麻酚（CBN）和大麻二酚（CBD），在有经验的大麻吸烟者中并未引起显著的剂量相关生理效应。然而，δ8-THC（75毫克）与支气管扩张、心动过速有关，且其引起的高峰兴奋程度低于δ9-四氢大麻酚（δ9-THC）。CBN和CBD与低剂量δ9-THC（5毫克）的组合未引起显著的支气管扩张，但对心率和“兴奋感”有相互作用。一项对每日服用δ9-THC（20毫克）、CBN（600毫克）和CBD（1200毫克）进行的为期20天的研究未表明对任何药物产生耐受性或耐受性逆转。我们得出结论，δ9-THC以及在较小程度上的δ8-THC具有急性支气管扩张活性，但CBN、CBD及其组合不能提供有效的支气管扩张作用。每日使用δ9-THC与临床耐受性无关。
